Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Lipella Pharmaceuticals Inc. | LP-10 (liposomal tacrolimus) | Oral lichen planus | Phase 2a | Data Released | Topical | N/A |
| Lipella Pharmaceuticals Inc. | LP-310 | Oral Lichen Planus (OLP) | Phase 2a | Data Released | Oral | N/A |
| Lipella Pharmaceuticals Inc. | LP-310 with tacrolimus | Oral graft-versus-host disease (GVHD) | Phase 2a | IND Clearance | oral | Immunosuppressant |
| Lipocine Inc. | TLANDO (LPCN 1021) | Men with low testosterone (Low T) | NDA Filing | Withdrawn | Oral | Endocrinology |
| Lipocine Inc. | LPCN 1154 (oral brexanolone) | Postpartum Depression | Phase 3 | Enrollment Initiation | Oral | Psychiatric |
| Lipocine Inc. | LPCN 1111 | Oral testosterone product | Phase 2b | Looking for Funding | Oral | Hormone Replacement |
| Lipocine Inc. | LPCN 2401 | Obesity, Chronic Weight Management | Phase 2 | Data Released | oral | Endocrinology |
| Lipocine Inc. | LPCN 2101 | Epilepsy | Phase 2 | Ongoing | Oral | Neurology |
